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Abstract
Background: The extent of enhanced bone marrow angiogenesis in chronic lymphocytic leukemia
(CLL) and relationship to proangiogenic factors and prognostic indicators is largely unexplored.
Methods: To further investigate the role of angiogenesis in CLL by evaluating the topography and
extent of angiogenesis in a group of CLL bone marrow biopsies, to study the expression of pro and
antiangiogenic vascular factors in CLL cells to more precisely document the cell types producing
these factors, and to evaluate the role, if any, of localized hypoxia in upregulation of angiogenesis
in CLL We used immunohistochemistry (IHC) (n = 21 pts) with antibodies to CD3 and CD20,
proangiogenic (VEGF, HIF-1a) and antiangiogenic (TSP-1) factors, and VEGF receptors -1 and -2 to
examine pattern/extent of CLL marrow involvement, microvessel density (MVD), and angiogenic
characteristics; flow cytometry (FC) was performed on 21 additional cases for VEGF and TSP-1.
Results: CLL patients had higher MVD (23.8 vs 14.6, p~0.0002) compared to controls (n = 10).
MVD was highest at the periphery of focal infiltrates, was not enhanced in proliferation centers,
and was increased irrespective of the presence or absence of cytogenetic/immunophenotypic
markers of aggressivity. By IHC, CLL cells were VEGF(+), HIF-1a (+), TSP-1(-), VEGFR-1(+), and
VEGFR-2(+). By FC, CLL cells were 1.4–2.0-fold brighter for VEGF than T cells and were TSP-1(-).
Conclusion: CLL demonstrates enhanced angiogenesis, with increased MVD, upregulated VEGF
and downregulated TSP-1. Upregulation of HIF-1a in all CLL cases suggests localized tissue hypoxia
as an important stimulant of microvessel proliferation. The presence of VEGF receptors on CLL
cells implies an autocrine effect for VEGF. Differences in MVD did not correlate with traditional
genetic/immunophenotypic markers of aggressiveness.
Introduction
Angiogenesis, the branching of new microvessels from
pre-existent larger blood vessels, is of major importance in
normal embryogenesis and in physiologic processes such
as ovulation and the menstrual cycle. Under normal con-
ditions, an organ system is kept at a set point in which the
pro- and antiangiogenic molecules are in a state of equi-
librium. In neoplasia, the set point may become unbal-
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anced in favor of proangiogenic molecules. This
"angiogenic switch" [1] favors the production of new
microvessels, thus facilitating tumor growth beyond 1–2
mm diameter, and metastasis of the malignant clone. A
number of molecules, including vascular endothelial
growth factor (VEGF), basic fibroblast growth factor
(bFGF), and hypoxia-inducible factor 1α (HIF-1α) have
been identified as positive regulators of angiogenesis.
These are kept in balance by negative regulators of angio-
genesis including thrombospondin-1 (TSP-1) [2] and
interferon β (IFNβ) [3].
Pathologic angiogenesis was recognized to be important
in the progression of solid tumors over 30 years ago [4].
More recently, abnormal angiogenesis has been identified
in a number of hematologic malignancies. Although stud-
ies are limited, an increasing body of evidence supports
the existence of increased tissue site angiogenesis in
chronic lymphocytic leukemia (CLL). An increase in
microvessel density, an index of angiogenic activity
defined by the number of microvessels per microscopic
high power field, was noted in CLL bone marrows by Kini
et al; the degree of angiogenesis correlated with Rai stage
[5]. Increased microvessel density has also been noted in
other sites including lymph nodes involved by CLL [6].
Vascular factors relevant in angiogenesis including VEGF
and bFGF have been reported in increased levels in serum
and urine of some CLL patients [5,7-9]. Kay et al report
increased VEGF and bFGF in the supernatant of CLL cells
grown in vitro and upregulation of mRNA encoding VEGF
and its receptors and bFGF, suggesting that angiogenic fac-
tors are important in the biology of the malignant B-cell
clone [10]. In addition to its role in angiogenesis, bFGF
appears to upregulate BCL-2 expression in CLL [11]. In
vitro evidence suggests that in a subset of CLL cases TSP-1
is expressed by a subset of CLL cells [12]. Microvessel den-
sity correlates with stage and progression free survival in
CLL [5] and increased expression of VEGF receptors and
bFGF correlate with clinical stage [7,13]. However, the
extent to which increased angiogenesis correlates with
known genetic and immunophenotypic prognostic fac-
tors in CLL is not known. In addition, similar studies to
those reviewed above have not been performed in the
bone marrow of CLL patients.
In hypoxic conditions, normal tissues express HIF-1α,
which upregulates expression of VEGF and other factors,
resulting in increased angiogenesis and increased oxygen
delivery to tissues [14]. In a deregulated system, abnor-
mally increased HIF-1α may likewise increase angiogen-
esis and it has been demonstrated that hypoxia exists in
normal marrows [15]. CLL cells have been demonstrated
to have the ability to produce significant levels of VEGF
under hypoxic conditions [12]. Also, cells from CLL-
derived lines have been shown to secrete HIF-1α [10].
Thus it is likely that hypoxia plays a role in CLL B-cell
secretion of VEGF.
The aforementioned studies suggest that angiogenesis
may be of major importance in CLL. A direct assessment
of pro- and antiangiogenic molecules, their receptors, and
the level of HIF-1α in relationship to the environment
where CLL is believed to originate, the bone marrow,
would add further credence to the argument that angio-
genesis is of importance in the pathophysiology of CLL.
Moreover, it would be possible to evaluate the expression
patterns of these molecules in relationship to the malig-
nant infiltrates, and to directly assess the degree and pat-
tern of microvessel density in the marrow.
The purpose of this study was to further investigate the
role of angiogenesis in CLL by evaluating the topography
and extent of angiogenesis in a group of CLL bone marrow
biopsies, in particular the relationship of microvessels to
the infiltrates. We also wanted to study the expression of
pro and antiangiogenic vascular factors in CLL cells to
more precisely document the cell types producing these
factors. To evaluate the role, if any, of localized hypoxia in
upregulation of angiogenesis in CLL, we also examined
the expression of the VEGF transcriptional regulator, HIF-
1α. Finally, in a subset of cases we correlated our findings
with genetic and phenotypic factors that have prognostic
significance in CLL.
Materials and Methods
Institutional review board
The following experiments were performed with the
approval of the Institutional Review Board of Northwest-
ern University Feinberg School of Medicine and the Mayo
Clinic.
Cases
We studied 42 adult patients with typical clinical, flow
cytometric, and morphologic evidence of CLL [16]. For
the purposes of this study we defined two groups.
Group 1 – CLL marrow immunohistochemical analysis
We retrospectively selected 28 bone marrow core biopsies
from 21 patients with a diagnosis of CLL who were also
being evaluated for disease status prior to beginning ther-
apy with the antiangiogenic drug thalidomide as part of a
North Central Cancer Treatment Group Center (NCCTG)
clinical study. Marrow specimens were decalcified and
paraffin-embedded sections cut at 5 μm intervals were
stained with hematoxylin-eosin for initial morphologic
evaluation. Immunohistochemistry was performed on
serial sections from the core biopsies using antibodies
against CD3 and CD20 (for evaluation of extent of mar-
row involvement by CLL), CD34 (for evaluation of micro-
vessel density), p53, VEGF, Hif-1α, TSP-1, and bFGF andDiagnostic Pathology 2008, 3:16 http://www.diagnosticpathology.org/content/3/1/16
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the VEGF receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1).
Manufacturer and clone details are summarized in Table
1. HIF-1α staining was performed using signal amplifica-
tion. All other immunohistochemistry was performed
using direct antibody labeling.
Analysis of microvessel density (MVD) was performed on
CD34-stained sections as described previously [5]. Briefly,
bone marrow biopsy sections were examined using a
model BH-50 Olympus Microscope (Tokyo, Japan) with a
60× objective and a 10× ocular lenses. The number of
microvessels per field was measured, and we noted
whether a given field was involved by CLL, uninvolved, or
partially involved. We also indicated whether a given field
included a proliferation center or was at the edge or center
of a nodular infiltrate. We compared the average (arith-
metic mean) microvessel density of involved versus unin-
volved fields in CLL cases and CLL versus normal cases
using the student T-test at the 5% confidence level. We
also noted the relative microvessel density in proliferation
centers versus involved fields not containing proliferation
centers and fields containing the edges of nodular infil-
trates versus the centers.
In an effort to correlate the results of marrow MVD analy-
sis with other CLL prognostic indicators, additional
patient material was used for genetic analysis for other
features with known prognostic significance. Fluorescence
in situ hybridization (FISH) analysis of patient cells was
performed using some commercial FISH probes (Vysis,
Downers Grove, IL) and some homebrew FISH probes to
detect the presence of two recurring abnormalities predic-
tive of poor prognosis in CLL, trisomy 12 and mutation of
chromosome 17p in the vicinity of the p53 locus, and a
common genetic marker predictive of a more favorable
course, abnormality of chromosome 13q14, using tech-
niques published elsewhere [17,18].
Flow cytometric immunophenotypic analysis of patient
blood samples was performed to assess lymphocyte
expression of CD38, a poor prognostic indicator in CLL.
Lymphocytes from patient samples were separated from
the other cellular elements using the ficoll-hypaque gradi-
ent technique, and were stained using a commercially
available phycoerythrin (PE) labeled anti-CD38 and fluo-
rescein isothiocyanate (FITC)-labeled anti-CD19 antibod-
ies (Becton Dickinson). Two-color analysis was
performed using a FACScan flow cytometer manufactured
by Becton-Dickinson. A positive result was defined by
CD38 expression in ≥ 20% of cells.
RNA extracted from patient bone marrow samples was RT-
PCR-amplified and sequence analysis of the cDNA of the
IgVH region was performed as previously reported [19].
Using a comparison to the V BASE sequence directory
using DNAPLOT software, cases with <2% deviation from
the most familiar germline Ig sequence were designated
"non mutated", the others as "mutated" type B-cell clones.
Group 2 – Flow cytometric analysis of CLL B-cells
21 additional cases with peripheral blood and/or bone
marrow involvement by CLL encountered in the clinical
population at Northwestern Memorial Hospital were
selected for analysis of p53, VEGF, HIF-1α, and TSP-1
(cells from Group 1 patients were unavailable for testing
for these antigens). Lymphocytes from patient samples
were separated from the other cellular elements using the
ficoll-hypaque technique. The lymphocytes were then
stored at -30°C until analysis. The antibodies were conju-
gated to fluorescein isothiocyanate (FITC), phycoeryth-
erin (PE), PE-cyanine 5 molecular conjugate (PE-CY5), or
phycoerythrin-Texas red molecular conjugate (ECD).
Detailed antibody information is summarized in Table 2.
To access the cytoplasmic antigens, the cells were treated
with Intreprep permeabilization reagents (Beckman Coul-
ter, Miami, FL) as recommended by the manufacturer.
Stock solutions of 200 ug/mL of VEGF and TSP-1 were
made, and 5 μL were used per sample. The secondary anti-
body for VEGF was anti rabbit Alexa 488 (Molecular
Probes, Eugene, OR). 10 μL were used per test. For Hif-1α,
a stock solution of 2.95 mg/mL was made. The solution
was diluted 1:10 in phosphate buffered saline, and 3.4 μL
were used for each sample. 2 ug of p53 antibody were
used per sample. Rat anti-Mouse IgG was used as the sec-
ondary antibody for TSP-1 and Hif-1α. 10 μ of anti CD5
and CD19 were used per sample. Four color flow cytomet-
ric immunophenotypic analysis was performed using an
instrument manufactured by Beckman Coulter.
To validate the performance of the angiogenesis-related
antibodies used in this study, flow cytometric analysis
identical to that described for patient and control samples
was also performed on cell lines with known expression
of the antigens in question. For VEGF, the breast cancer-
derived MCF7 cells were used [20]. The human umbilical
vein endothelial cell-derived cell line HUVEC was used for
Table 1: Antibodies used for immunohistochemistry
Antibody Manufacturer Class Clone
CD3 Dako, Glostrup, Denmark IgG Polyclonal
CD20 Dako, Glostrup, Denmark IgG2a L26
CD34 Dako, Glostrup, Denmark IgG1 QBend 10
p53 Dako, Glostrup, Denmark IgG2b D0–7
VEGF Santa Cruz, Santa Cruz, CA IgG Polyclonal
HIF-1α Novus, Littleton, CO IgG2b H1α67
TSP-1 NeoMarkers, Fremont, CA IgG1 A6.1
bFGF R&D, Minneapolis, MN IgG2A 10043
VEGF-R1 NeoMarkers, Fremont, CA IgG Polyclonal
VEGF-R2 NeoMarkers, Fremont, CA IgG PolyclonalDiagnostic Pathology 2008, 3:16 http://www.diagnosticpathology.org/content/3/1/16
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TSP-1 [21]. The SV40 (simian virus 40) -transformed cell
line HSF4-T12 was used to assess expression of p53 [22].
Controls
A control group consisting of 10 patients was identified
with bone marrow biopsies that were not involved by a
malignant process, including CLL. The biopsies were proc-
essed, cut, and stained with anti-CD34 in an identical
fashion to that described for the cases.
A second control group of 10 bone marrow/peripheral
blood cases was selected from the clinical case load of
Northwestern Memorial Hospital. All cases had an identi-
fiable benign B lymphocyte population and had no evi-
dence of malignancy. Lymphocytes were separated from
the other cellular elements as described above and were
analyzed by flow cytometry in an identical fashion to that
described for the cases. Whole peripheral blood from two
additional cases was analyzed without prior separation of
lymphocytes for assessment of granulocyte VEGF expres-
sion.
Results
Histopathology
Cases of CLL from group 1 had marrow involvement by
CLL B-cells ranging from <10% to100% of the marrow
cellularity. 6 patients had one or more proliferation/
growth centers, which contained cells with slightly larger
overall size, slightly dispersed nuclear chromatin, promi-
nent nucleoli, and an increased number of mitotically
active cells. Patterns of marrow involvement included dif-
fuse (12 biopsies), interstitial (6 biopsies), nodular (7
biopsies), or a combination of patterns (3 biopsies).
Microvessel density (MVD)
Compared to a control group of 10 cases, the mean MVD
of the 21 group 1 CLL cases was higher than that of the
normal control group. The average MVD in the CLL group
was 23.8 (range 13.4–35.9) while the average of the con-
trol group was 14.6 (range 9.2–22.1). Although there was
some overlap in average MVD in the CLL and control
groups, the overall difference in mean microvessel density
between the CLL and control groups was statistically sig-
nificant with a p value of 0.0002 using the 2-tailed stu-
dents T-test.
The distribution of microvessels in the CLL biopsies dif-
fered somewhat from that in the control patients as the
latter had distribution of blood vessels in a uniform fash-
ion throughout the biopsies. The MVD was highest at the
periphery of focal infiltrates, as has been described in
solid tumors (Figure 1)[23]. In the 6 CLL cases with ≥ 1
uninvolved high power field, the average of the involved
fields were slightly higher than the uninvolved fields (24
vs. 21 microvessels per high power field); this difference
was not statistically significant. In cases with proliferation
centers, MVD was not enhanced within the proliferation
centers relative to the rest of the infiltrate, and approxi-
mated that of uninvolved areas (Figure 2).
VEGF
CLL cells in all 21 cases tested by immunohistochemistry
were consistently VEGF positive (Figure 3). Marrow,
which could be easily distinguished from the marrow
lymphocytes, had more intense VEGF reactivity, and
erythroid precursor cells were negative. 21 cases were
examined by flow cytometry for VEGF expression (Figure
4). The level of VEGF expression by the CD19+ B cells in
the control cases was equal to that of the CD19- T cells. A
Increased Microvessel Density in CLL vs Controls Figure 1
Increased Microvessel Density in CLL vs Controls. 
Microvessel density was highest at the periphery of focal infil-
trates. This is a case of CLL (left panel) with nodular lym-
phoid infiltrates. The image shows an increase in CD34+ 
microvessels at the leading edge of an infiltrate. In the con-
trol tissue (right panel), the microvessel density is somewhat 
less.
Table 2: Antibodies used for flow cytometry
Antibody Manufacturer Class Clone Fluorochrome
CD5 Beckman Coulter, San Diego, CA IgG2a BL1a PC5
CD19 Beckman Coulter, San Diego, CA IgG1 J4.119 ECD
p53 Dako, Glostrup, Denmark IgG2b D0–7 FITC
TSP-1 NeoMarkers, Fremont, CA IgG1 A6.1 PE
VEGF Santa Cruz, Santa Cruz, CA IgG polyclonal FITC
Abbreviations: PC5- phycoerythrin-cyanin 5.1; ECD- PE-Texas red; FITC- fluorescein isothiocyanate; PE- phycoerythrin.Diagnostic Pathology 2008, 3:16 http://www.diagnosticpathology.org/content/3/1/16
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plot of VEGF versus CD19 in one of the CLL cases is illus-
trated in the right panel of Figure 3. The CD19+ CLL cells
were 1.4–2.0× brighter for VEGF than the CD19-CD5+ T
cells in the same samples.
VEGFR-1 (Flt-1)
The 21 group 1 cases were evaluated for VEGFR-1 expres-
sion by immunohistochemistry (Figure 5). In all cases,
granulocytes demonstrated intense cytoplasmic reactivity,
scattered erythroid precursors had a predominantly mem-
branous pattern of staining, and megakaryocytes had faint
cytoplasmic reactivity. Endothelial cells, which could be
identified in most cases, were positive and served as useful
internal positive controls. Lymphocyte staining for
VEGFR-1 was variable and highlighted only a minority of
cells in most cases.
MVD was highest at the periphery of focal infiltrates, was
not enhanced in proliferation centers, and was increased
irrespective of the presence or absence of cytogenetic/
immunophenotypic markers of aggressivity. By IHC, CLL
cells were VEGF(+), HIF-1a (+), TSP-1(-), VEGFR-1(+),
and VEGFR-2(+). By FC, CLL cells were 1.4–2.0-fold
brighter for VEGF than T cells and were TSP-1(-). CLL
demonstrates enhanced angiogenesis, with increased
MVD, upregulated VEGF and downregulated TSP-1.
Upregulation of HIF-1a in all CLL cases suggests localized
tissue hypoxia as an important stimulant of microvessel
proliferation. The presence of VEGF receptors on CLL cells
implies an autocrine effect for VEGF. Differences in MVD
did not correlate with traditional genetic/immunopheno-
typic markers of aggressivity.
VEGFR-2 (KDR, Flk-1)
In the 21 group 1 cases, a differential pattern of staining
was identified (Figure 5). Granulocytes demonstrated the
most intense reactivity. Erythroid precursors and meg-
akaryocytes had a weaker pattern of reactivity compared
to granulocytes that did not appear distinctly membra-
nous. In most cases, only scattered cells in the infiltrates
were positive, with the exception of two cases in which the
vast majority of lymphocytes were positive. The MVD of
these two cases did not markedly differ from the other
cases in this group.
HIF-1 α
The 21 group 1 cases were evaluated for HIF-1 α expres-
sion. Lymphocytes from all cases were positive. Other
marrow hematopoeitic elements were negative, with the
exception of mast cells (Figure 6).
TSP-1
CLL cells in all cases tested for TSP-1 expression by IHC
were negative. Megakaryocytes were useful positive inter-
nal controls (Figure 7). The uniform TSP-1 negativity of
CLL cells was also noted using flow cytometry. All 21 cases
tested had similar results. In contrast, HUVEC cells, which
are known to express TSP-1, were positive by flow cytom-
etry (Figure 7).
bFGF
A differential pattern of staining was noted in the 21
group one cases. The granulocytes were intensely positive,
CLL Cells Express VEGF Figure 3
CLL Cells Express VEGF. A) CLL Cells in all 21 cases 
tested by immunohistochemistry were consistently VEGF 
positive. The majority of the cells in this field are lym-
phocytes which are VEGF positive. Granulocytes had more 
intense VEGF reactivity, and erythroid cells, as seen at the 
center of the field, were negative.
Microvessel Density is not Enhanced in Proliferation Centers Figure 2
Microvessel Density is not Enhanced in Proliferation 
Centers. A proliferation center is present at the center of 
the field, which has a lower number of CD34+ microvessels 
than surrounding areas.Diagnostic Pathology 2008, 3:16 http://www.diagnosticpathology.org/content/3/1/16
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the lymphocytes had fainter staining, and erythroid pre-
cursors were negative.
P53
In two cases, the majority of lymphocytes in the infiltrates
were positive. The other nineteen cases were negative or
demonstrated only rare scattered positive cells.
Interphase cytogenetics
Correlation with genetic and immunophenotypic prog-
nostic factors was performed on18 Group 1 cases, using
probes as described elsewhere [18].
FISH was performed for analysis using two abnormalities
predictive of poor prognosis, trisomy 12 (D12Z3 for chro-
mosome 12 centromere and MDM2 for 12q15) and
abnormalities of chromosome 17 (p53at 17p13.1 and
D17Z1 for the chromosome 17 centromere), and a
marker predictive of a more favorable course, abnormality
of chromosome 13q (D13S319 at 13q14 and LAMP1 at
13q34). Cases with trisomy 12 (2 cases) or chromosome
17 abnormalities (1 case) had a similar mean MVD to 15
cases with partial loss of chromosome 13q (13 cases) or
no demonstrable abnormalities using these probes (2
cases). The case with abnormal chromosome 17 also had
increased p53 staining by immunohistochemistry. No
cases had evidence of CCND1/IgH [t(11;14)] fusion [18].
CD38 and/or IgVH analysis
15 Group 1 cases were tested for CD38 expression and or
IgVH gene mutation. Eight cases with >20% of the CLL
cells expressing CD38 and/or IgVH gene in germline con-
figuation, both of which are poor indicators, had an aver-
age MVD that was similar to 7 cases that were both CD38
negative and had mutated IgVH.
Discussion
CLL is a complex disease characterized by a progressive
accumulation of CD5+ B-lymphocytes in the peripheral
blood, bone marrow, lymph nodes, and other sites.
Another important host system for the survival of the
malignant population is the vasculature of the bone mar-
row and other involved sites. We report the results of a
series of experiments performed on bone marrow tre-
phine biopsies and bone marrow/peripheral blood sam-
ples from patients with CLL that support earlier
Bright VEGF Expression is Identified in CLL Cells by Flow Cytometry Figure 4
Bright VEGF Expression is Identified in CLL Cells by Flow Cytometry. 21 cases were examined by flow cytometry 
for VEGF expression. The panel on the left is a plot of VEGF vs CD19 expression in a control case. The level of VEGF expres-
sion by the CD19+ B cells in the control cases was equal to that of the CD19- T cells. A plot of VEGF vs CD19 in one of the 
CLL cases is illustrated in the right panel. The CD19+ CLL Cells were 1.4–2.0× Brighter than the CD19-CD5+ T cells in the 
same samples. VEGFR-2 (KDR, Flk-1): In most cases, only scattered cells in the infiltrates were positive, with the exception 
of two cases, one of which is illustrated, in which the vast majority of lymphocytes were positive. The microvessel density of 
these two cases did not markedly differ from the other cases in this group.Diagnostic Pathology 2008, 3:16 http://www.diagnosticpathology.org/content/3/1/16
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observations that dysregulated angiogenesis is a common
phenomenon in this disease. The proangiogenic factors
VEGF and HIF-1α are expressed by the malignant cells and
are associated with increased microvessel production in
the bone marrow milieu. The potent antiangiogenic factor
TSP-1 is not produced by the malignant cells in the mar-
row. In addition to endothelial surfaces, VEGFR-1 and
VEGFR-2 are also expressed on the CLL cells, implying
that VEGF may act both on the normal endothelial cells
and on the malignant population.
Micovessel density is increased throughout. Several obser-
vations suggest a relatively localized paracrine effect of
proangiogenic factors in CLL bone marrows and the pos-
sible importance of angiogenesis in the metabolically
active edges of CLL infiltrates. Although most cases had a
diffuse growth pattern, in cases with a nodular pattern of
growth, the edges of the nodules had a relatively higher
microvessel density than the centers or uninvolved areas
of marrow.
Observations such as these are also noted in other malig-
nancies, including both hematologic neoplasms and solid
tumors. The explanation for this lies in the production of
proangiogenic growth factors and hormones by tumor
cells and/or the nontumoral matrix [24-26]. In addition,
the production of growth factors in the tumor cells is often
controlled by transcriptional regulators, the most promi-
nent of which appears to be HIF-1α.
A major proangiogenic factor is VEGF, a homodimeric
glycoprotein (molecular weight ~45 kD) encoded by a
gene on chromosome 6p21-p12 [27,28] which stimulates
angiogenesis and vascular permeability by interacting
with the tyrosine kinase receptor-2 (VEGFR-2 or KDR/Flk-
1) and -1 (VEGFR-1 or Flt-1) [29]. VEGF expression was
apparent in both the granulocytes and lymphocytes of the
CLL cases. Although there may be a slight increase in
microvessel density in areas of involvement, there is an
overall increase in microvessel density thoughout. The
mere production of proangiogenic factors is not sufficient
to explain the differential MVD noted in our patients.
Hif-1 α Expression by CLL cells Figure 6
Hif-1 α Expression by CLL cells. The 21 group 1 cases 
were evaluated for Hif-1 α expression. Lymphocytes from all 
cases were positive.
VEGF receptors. VEGFR-1 (Flt-1) Figure 5
VEGF receptors. VEGFR-1 (Flt-1). Lymphocyte staining was variable and highlighted only a minority of cells in most cases. 
In the case illustrated in the left panel, many cells in the infiltrate were positive. Very few positive cells were present in the case 
illustrated in the middle panel. In all cases, granulocytes demonstrated intense cytoplasmic reactivity, scattered erythroid pre-
cursors had a predominantly membranous pattern of staining, and megakaryocytes had faint cytoplasmic reactivity. Endothelial 
cells, which could be identified in most cases, were positive and served as useful internal positive controls. VEGFR-2 (KDR, 
Flk-1): In most cases, only scattered cells in the infiltrates were positive, with the exception of two cases, one of which is illus-
trated in the right panel, in which the vast majority of lymphocytes were positive. The microvessel density of these two cases 
did not markedly differ from the other cases in this group.Diagnostic Pathology 2008, 3:16 http://www.diagnosticpathology.org/content/3/1/16
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Another possible explanation for the localized microves-
sel production in CLL is the differential expression of
other pro- and antiangiogenic factors such as HIF-1α and
TSP-1 that may act in concert with VEGF to induce neovas-
cularization.
VEGF is a mitogen that presumably could have activity in
any cells expressing the VEGF receptors VEGFR-1 (Flt-1)
and VEGFR-2 (Flk-1), and co-expression of at least one of
its receptors supports the theory of an autocrine role for
the cytokine in addition to the paracrine role associated
with angiogenesis [30-32]. Knowledge of the extent of
VEGF receptor expression in normal tissues is currently
limited, but VEGFR-2 appears to demonstrate lineage
restriction that is limited to endothelial cells in normal
conditions [33], and is expressed in certain leukemias
[34]. In CLL, we have noted that both receptor classes are
expressed on the malignant cells, and Kay et al have
shown that mRNA encoding the VEGF receptors is upreg-
ulated in CLL cells [12]. In the model proposed by Kay et
al VEGF acts autocrinously, since two different classes of
VEGF receptors are expressed on CLL cells. We provide
further evidence of this by demonstrating the presence of
VEGFR-1 and VEGFR-2 immunohistochemically in the
malignant cells. In this regard, VEGF could act like the
receptors for the growth factors bFGF and platelet-derived
growth factor (PDGF), which are expressed in a wide vari-
ety of cell types and have a broad spectrum of mitogenic
activity [28]. Interestingly, there was a broad range of
VEGF receptor expression in the lymphocytes. In some
cases, large numbers of cells expressed VEGF receptors and
in others receptor expression was virtually absent. We did
not find a clear association of this finding with stage or
MVD; however this may represent evidence of heterogene-
ous acquisition of an autocrine phenotype by CLL cells.
In normal systems, expression of the various angiogen-
esis-related factors is regulated, resulting in a dynamic
equilibrium in which pro-and antiangiogenic factors are
balanced. In conditions of localized tissue hypoxia, VEGF
expression is enhanced by the transcription regulator HIF-
1α. Increased expression of HIF-1α mRNA was noted by
Kay et al in CLL cells grown in vitro [12]. In our cases, a
speckled pattern of staining with antibody directed
against HIF-1 α was consistently present in CLL cells.
Other cells were negative, with the exception of mast cells,
which have a proven role in angiogenesis [35,36],
although production of HIF-1α by mast cells has not pre-
viously been reported. Because granulocyte staining for
HIF-1α in our specimens was not observed, it seems
unlikely that the cytoplasmic mast cell staining observed
in our patients is the result of nonspecific (antibody-inde-
pendent) interactions. The pattern of lymphocyte staining
with this antibody suggests a tight clustering of antigens
within the CLL cytoplasm, the significance of which is cur-
rently unknown.
In the smaller number of cases we have tested for the FISH
detectable abnormalities, immunoglobulin mutational
status, and immunophenotypic parameters predictive of
TSP-1 is not expressed by CLL cells Figure 7
TSP-1 is not expressed by CLL cells. CLL cells in all cases tested for TSP-1 expression by immunohistochemistry were 
negative. In the left panel is a case of CLL with a field of TSP-1 negative lymphocytes. At the center of this field is an internal 
positive control, a megakaryocyte. The TSP-negativity of CLL cells was verified by flow cytometry. All 21 cases tested had 
results similar to the cases illustrated in the middle panel. HUVEC cells, which are known to express TSP-1, were positive by 
flow cytometry (right panel).Diagnostic Pathology 2008, 3:16 http://www.diagnosticpathology.org/content/3/1/16
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poor prognosis, however, we found no difference in MVD
between those patients with one or more of these poor
prognostic indicators and their angiogenic status as deter-
mined by MVD.
In contrast to the apparent lack of correlation of these
prognostic indicators with angiogenic status, Kini et al
have identified that degree of angiogenesis, using MVD as
an index, correlated with stage [5], and Molica et al have
demonstrated that MVD at diagnosis correlates with
upstaging and progression-free survival [37]. These find-
ings suggest that dysregulation of angiogensis is common
in CLL, and as such may represent an early event in leuke-
mogenesis. Since the clinical course of CLL may last many
years, the acquisition of other genetic mutations may aug-
ment the earlier dysregulation of angiogenesis, account-
ing for the increased MVD seen in higher stage
individuals. Patients with a shorter duration of disease
may have more modest changes in angiogenic status.
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